查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668040

皰疹性咽峽炎治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、病毒、最終用戶、地區和競爭細分，2020-2030 年預測

Herpangina Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Virus, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球皰疹性咽峽炎治療市場價值為 18.9 億美元，預計到 2030 年將達到 28.6 億美元，複合年成長率為 7.14%。 由於病毒感染的盛行率不斷上升，尤其是在兒童中，全球皰疹性咽峽炎治療市場正在穩步成長。皰疹性咽峽炎是由柯薩奇病毒 A 等腸病毒引起的，會導致咽喉疼痛性潰瘍和發燒，需要透過止痛藥、退燒藥和補水療法進行症狀治療。皰疹性咽峽炎的發病率上升，加上父母對病毒感染的認知不斷提高，推動了對有效治療方案的需求。醫療保健提供者強調早期診斷和適當的支持性護理，從而促進市場擴張。非處方止痛藥的供應和兒科醫療設施的進步進一步支持了市場的成長，確保及時管理受影響個體的症狀。

市場概況
預測期 2026-2030
2024 年市場規模 18.9 億美元
2030 年市場規模 28.6 億美元
2025-2030 年複合年成長率 7.14％
成長最快的領域 柯薩奇病毒A
最大的市場 北美洲

遠距醫療和數位醫療解決方案的日益普及，大大提高了兒科諮詢的機會，使得能夠及時診斷和治療皰疹性咽峽炎病例。抗病毒療法的持續研究和有針對性的治療方法的開發有望徹底改變市場。人們對預防性醫療保健的日益關注，包括腸病毒相關感染的疫苗接種研究，提供了一個潛在的成長途徑。製藥公司積極投入兒科藥物配方，確保為年輕患者提供安全有效的治療方案。醫療基礎設施的擴張和醫療支出的上升正在提高醫療服務的可近性，尤其是在新興經濟體。

低度開發地區對皰疹性咽峽炎症狀和治療方案的認知有限仍然是一個重大挑戰。由於缺乏針對皰疹性咽峽炎的特定抗病毒藥物，導致人們只能依賴對症治療，從而限制了治療進展。對自我藥療和不當使用止痛藥的擔憂進一步阻礙了有效的疾病管理。兒科藥物核准的嚴格監管要求增加了新型治療方案的開發和商業化的複雜性。市場也面臨與季節性疫情相關的挑戰，這造成需求波動，使得醫療保健系統難以保持一致的準備。應對這些挑戰需要醫療保健組織、政府和製藥公司之間的共同努力，以提高意識、研究資金和治療的可及性。

主要市場促進因素

皰疹性咽峽炎盛行率高

主要市場挑戰

診斷工具不足

主要市場趨勢

抗病毒療法的進展

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球皰疹性咽峽炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療（局部麻醉劑、布洛芬或對乙醯氨基酚、其他治療）
    • 依病毒分類（柯薩奇病毒 A、柯薩奇病毒 B、腸病毒 71、埃可病毒）
    • 按最終使用者（醫院、家庭護理、專科診所、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按治療
    • 病毒
    • 按最終用戶
    • 按地區

第 5 章：亞太地區皰疹性咽峽炎治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按治療
    • 病毒
    • 按最終用戶
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲皰疹性咽峽炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美皰疹性咽峽炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 8 章：南美洲皰疹性咽峽炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲皰疹性咽峽炎治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 12 章：全球皰疹性咽峽炎治療市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Gilead Sciences Inc
  • Johnson and Johnsons
  • Merck & Co. Inc
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Sanofi SA
  • Novartis AG
  • Mitsubishi Tanabe Pharma Corporation
  • F. Hoffmann-La Roche Ltd

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 18977

Global Herpangina Treatment Market was valued at USD 1.89 Billion in 2024 and is expected to reach USD 2.86 Billion in the forecast period with a CAGR of 7.14% through 2030. The Global Herpangina Treatment Market is witnessing steady growth due to the increasing prevalence of viral infections, particularly among children. Herpangina, caused by enteroviruses such as Coxsackievirus A, leads to painful ulcers in the throat and fever, requiring symptomatic management through pain relievers, antipyretics, and hydration therapy. The rising incidence of herpangina, coupled with growing parental awareness about viral infections, is fueling demand for effective treatment options. Healthcare providers are emphasizing early diagnosis and appropriate supportive care, contributing to market expansion. The availability of over-the-counter pain relief medications and advancements in pediatric healthcare facilities further support market growth, ensuring timely management of symptoms in affected individuals.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.89 Billion
Market Size 2030USD 2.86 Billion
CAGR 2025-20307.14%
Fastest Growing SegmentCoxsackie Virus A
Largest MarketNorth America

The increasing adoption of telemedicine and digital healthcare solutions has significantly enhanced access to pediatric consultations, allowing for prompt diagnosis and management of herpangina cases. Continuous research in antiviral therapies and the development of targeted treatment approaches are expected to revolutionize the market. The rising focus on preventive healthcare, including vaccination research for enterovirus-related infections, presents a potential growth avenue. Pharmaceutical companies are actively investing in pediatric drug formulations, ensuring safe and effective treatment solutions tailored to young patients. The expansion of healthcare infrastructure and rising healthcare expenditure are driving higher accessibility to medical services, particularly in emerging economies.

Limited awareness about herpangina symptoms and treatment options in underdeveloped regions remains a major challenge. The absence of specific antiviral drugs for herpangina leads to reliance on symptomatic care, limiting treatment advancements. Concerns regarding self-medication and improper use of pain relief medications further hinder effective disease management. Stringent regulatory requirements for pediatric drug approvals add complexities to the development and commercialization of novel treatment solutions. The market also faces challenges related to seasonal outbreaks, which create fluctuations in demand, making it difficult for healthcare systems to maintain consistent preparedness. Addressing these challenges requires collaborative efforts among healthcare organizations, governments, and pharmaceutical companies to improve awareness, research funding, and treatment accessibility.

Key Market Drivers

High Prevalence of Herpangina

The high prevalence of herpangina is a compelling driver behind the robust growth of the Global Herpangina Treatment Market. Herpangina, a viral infection primarily affecting children, is characterized by painful throat sores, fever, and discomfort, making effective treatment imperative. The contagious nature of this illness ensures a consistent and sizable patient pool seeking medical attention, thereby fostering a constant demand for treatment options.

Children, especially those in school and daycare settings, are particularly susceptible to herpangina due to its ease of transmission through close contact. As a result, healthcare providers often encounter cases of herpangina, further underscoring the importance of developing effective treatments. The global prevalence of herpangina ensures that pharmaceutical companies and medical device manufacturers remain highly motivated to invest in research, development, and innovation in this niche healthcare sector.

Additionally, medical device manufacturers contribute to the market by developing diagnostic tools and equipment that aid healthcare professionals in the rapid and accurate identification of herpangina-causing viruses. These tools facilitate early intervention and prompt treatment, particularly in crowded and high-risk environments such as schools and daycare centers.

While specific recent statistics on herpangina prevalence are limited, data on related enteroviral infections provide insight into the disease's impact. For instance, during a 1998 outbreak in Taiwan, a total of 129,106 cases of hand, foot, and mouth disease (HFMD) and herpangina were reported. This highlights the substantial burden such viral infections can impose on healthcare systems. Given the cyclical nature of enteroviral outbreaks, similar patterns may be observed in subsequent years, underscoring the ongoing need for effective herpangina treatments. In summary, the persistent and widespread occurrence of herpangina, especially among children in communal settings, drives continuous demand for effective treatments. This demand propels pharmaceutical and medical device companies to innovate and develop targeted therapies and diagnostic tools, thereby contributing to the growth of the Global Herpangina Treatment Market.

Key Market Challenges

Inadequate Diagnostic Tools

The Global Herpangina Treatment Market, dedicated to addressing the medical needs of individuals suffering from the viral infection herpangina, faces a significant hurdle in the form of inadequate diagnostic tools. Herpangina is a contagious illness primarily affecting children and is characterized by painful throat sores, fever, and discomfort. Timely and accurate diagnosis is essential for effective treatment and containment of the disease, but the current diagnostic landscape presents challenges that hinder the market's progress.

One of the primary challenges in the herpangina treatment market is the absence of rapid and reliable diagnostic tools for identifying the viruses responsible for herpangina, notably the Coxsackievirus. Unlike some other infectious diseases with readily available diagnostic tests, herpangina lacks specific point-of-care diagnostic options. As a result, healthcare professionals often face delays in confirming a herpangina diagnosis, leading to potential misdiagnosis or the spread of the virus in high-risk environments like schools and daycare centers.

The limited availability of diagnostic tools can exacerbate the challenges associated with herpangina treatment. Without a rapid and definitive diagnosis, healthcare providers may resort to empiric treatments that focus on symptom management rather than targeting the underlying viral infection. This approach not only increases the risk of incorrect treatments but also delays the initiation of antiviral therapies, if applicable.

Moreover, inadequate diagnostic tools can hinder the ability to isolate infected individuals promptly, which is crucial in containing outbreaks, especially in settings where herpangina can easily spread among children. Without efficient diagnostic tests, identifying and isolating cases becomes a manual and time-consuming process, potentially allowing the virus to spread further.

Key Market Trends

Advancements in Antiviral Therapies

Advancements in antiviral therapies are playing a pivotal role in boosting the Global Herpangina Treatment Market. Herpangina, a viral infection primarily affecting children and characterized by painful throat sores, fever, and general discomfort, has long presented a challenge to healthcare providers due to its contagious nature and the lack of specific treatment options. However, recent strides in antiviral therapies are transforming the landscape of herpangina treatment.

Pharmaceutical companies are dedicating significant resources to research and develop novel antiviral drugs tailored specifically for herpangina-causing viruses, notably the Coxsackievirus. These advancements aim to address the root cause of herpangina by inhibiting the replication and spread of the virus within the body. By targeting the viral infection directly, these antiviral drugs not only alleviate the symptoms but also reduce the duration of the illness.

One of the significant advantages of these advanced antiviral therapies is their potential to combat drug-resistant strains of the virus. Over time, viruses like Coxsackievirus can adapt and become resistant to existing medications, rendering them less effective. The development of new antiviral compounds with diverse mechanisms of action helps mitigate the risk of resistance, ensuring that patients receive treatment that remains efficacious.

Additionally, these advancements in antiviral therapies contribute to enhancing the overall quality of care for individuals affected by herpangina. By shortening the duration of the illness and reducing the severity of symptoms, patients experience quicker relief and a more comfortable recovery process. This not only improves their well-being but also reduces the burden on healthcare systems by minimizing hospitalizations and outpatient visits.

Furthermore, these innovative antiviral therapies provide healthcare professionals with more effective tools for managing herpangina cases. They can confidently prescribe targeted antiviral medications that address the underlying viral infection, offering patients a more tailored and comprehensive treatment approach.

Key Market Players

  • Gilead Sciences Inc
  • Johnson and Johnsons
  • Merck & Co. Inc
  • Pfizer Inc.
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • Sanofi S.A
  • Novartis AG
  • Mitsubishi Tanabe Pharma Corporation
  • F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Herpangina Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpangina Treatment Market, By Treatment:

  • Topical Anesthetics
  • Ibuprofen or Acetaminophen
  • Other Treatments

Herpangina Treatment Market, By Virus:

  • Coxsackie Virus A
  • Coxsackie Virus B
  • Enterovirus 71
  • Echovirus

Herpangina Treatment Market, By End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Herpangina Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpangina Treatment Market.

Available Customizations:

Global Herpangina Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Herpangina Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Other Treatments)
    • 4.2.2. By Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus)
    • 4.2.3. By End User (Hospitals, Homecare, Specialty Clinics, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Treatment
    • 4.3.2. By Virus
    • 4.3.3. By End User
    • 4.3.4. By Region

5. Asia Pacific Herpangina Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment
    • 5.2.2. By Virus
    • 5.2.3. By End User
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Herpangina Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment
        • 5.3.1.2.2. By Virus
        • 5.3.1.2.3. By End User
    • 5.3.2. India Herpangina Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment
        • 5.3.2.2.2. By Virus
        • 5.3.2.2.3. By End User
    • 5.3.3. Australia Herpangina Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment
        • 5.3.3.2.2. By Virus
        • 5.3.3.2.3. By End User
    • 5.3.4. Japan Herpangina Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment
        • 5.3.4.2.2. By Virus
        • 5.3.4.2.3. By End User
    • 5.3.5. South Korea Herpangina Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment
        • 5.3.5.2.2. By Virus
        • 5.3.5.2.3. By End User

6. Europe Herpangina Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Virus
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Herpangina Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Virus
        • 6.3.1.2.3. By End User
    • 6.3.2. Germany Herpangina Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Virus
        • 6.3.2.2.3. By End User
    • 6.3.3. Spain Herpangina Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Virus
        • 6.3.3.2.3. By End User
    • 6.3.4. Italy Herpangina Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment
        • 6.3.4.2.2. By Virus
        • 6.3.4.2.3. By End User
    • 6.3.5. United Kingdom Herpangina Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment
        • 6.3.5.2.2. By Virus
        • 6.3.5.2.3. By End User

7. North America Herpangina Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Virus
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Herpangina Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Virus
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Herpangina Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Virus
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Herpangina Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Virus
        • 7.3.3.2.3. By End User

8. South America Herpangina Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Virus
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Herpangina Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Virus
        • 8.3.1.2.3. By End User
    • 8.3.2. Argentina Herpangina Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Virus
        • 8.3.2.2.3. By End User
    • 8.3.3. Colombia Herpangina Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Virus
        • 8.3.3.2.3. By End User

9. Middle East and Africa Herpangina Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Virus
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Herpangina Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Virus
        • 9.3.1.2.3. By End User
    • 9.3.2. Saudi Arabia Herpangina Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Virus
        • 9.3.2.2.3. By End User
    • 9.3.3. UAE Herpangina Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Virus
        • 9.3.3.2.3. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Herpangina Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Gilead Sciences Inc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Johnson and Johnsons
  • 14.3. Merck & Co. Inc
  • 14.4. Pfizer Inc.
  • 14.5. AbbVie Inc.
  • 14.6. Vertex Pharmaceuticals Incorporated
  • 14.7. Sanofi S.A
  • 14.8. Novartis AG
  • 14.9. Mitsubishi Tanabe Pharma Corporation
  • 14.10. F. Hoffmann-La Roche Ltd

15. Strategic Recommendations

16. About Us & Disclaimer